Camptothecin analogues: studies from The Johns Hopkins Oncology Center

1994 ◽  
Vol 34 (S1) ◽  
pp. S53-S57 ◽  
Author(s):  
William J. Slichenmyer ◽  
Eric K. Rowinsky ◽  
Louise B. Grochow ◽  
Scott H. Kaufmann ◽  
Ross C. Donehower
Keyword(s):  
Oncology Center ◽  
Camptothecin Analogues ◽  
Johns Hopkins Oncology

scholarly journals Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG

Blood ◽  
1988 ◽  
Vol 72 (2) ◽  
pp. 621-627 ◽  
Author(s):  
HK Holland ◽  
JR Wingard ◽  
WE Beschorner ◽  
R Saral ◽  
GW Santos
Keyword(s):  
Bone Marrow ◽  
Bronchiolitis Obliterans ◽  
Marrow Transplant ◽  
Host Disease ◽  
Allogeneic Bmt ◽  
Serum Igg ◽  
Ventilatory Failure ◽  
Oncology Center ◽  
Low Serum ◽  
Johns Hopkins Oncology

The records of 549 bone marrow transplant (BMT) patients at The Johns Hopkins Oncology Center during a 9-year period were reviewed to determine the incidence of bronchiolitis obliterans (BrOb). Seven patients had BrOb. All seven died, and BrOb was a contributing cause of death in six patients. Only recipients of allogeneic BMT were at risk for developing BrOb (2% incidence). Three cases were incidentally discovered at autopsy in patients who died less than 120 days after BMT from ventilatory failure owing to interstitial pneumonitis. Four cases were patients who died greater than 120 days after BMT. Of this latter group, all had overt chronic graft-v-host disease (CGVHD). Among 120 day survivors of allogeneic BMT, 6% of those with CGVHD developed BrOb as compared with none of those without CGVHD (P = .008). Five percent of patients with reduced IgG levels at day 120 developed BrOb as compared with none of those with normal IgG (P = .04). The incidence of BrOb in 120-day survivors was 14% (4 of 29) in patients with both CGVHD and decreased serum IgG, whereas patients with CGVHD only (0 of 25), those with decreased IgG levels only (0 of 53), and those with no CGVHD and normal IgG levels (0 of 70) did not develop BrOb.

Regionalization of Cancer Control Efforts in the U.S.A.

1981 ◽  
Vol 2 (1) ◽  
pp. 35-49
Author(s):  
Thomas W. Elwood ◽  
T. Phillip Waalkes ◽  
William P. Vaughan
Keyword(s):  
Community Education ◽  
Cancer Control ◽  
Control Program ◽  
Improve Patient Care ◽  
Cancer Centers ◽  
Integrated Approaches ◽  
Cancer Control Program ◽  
Oncology Center ◽  
Improve Patient ◽  
Johns Hopkins Oncology

The Johns Hopkins Oncology Center, one of the first of the nation's twenty-one Comprehensive Cancer Centers, established a cancer control program to mobilize resources to improve patient care and prevent the occurrence of neoplastic diseases. Initial efforts were based on the results of a series of investigations conducted in four communities. Findings from these studies were then converted into a series of programmatic interventions. The strategy included integrated approaches to creating a community education program within the overall effort.

scholarly journals Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG

Blood ◽  
1988 ◽  
Vol 72 (2) ◽  
pp. 621-627 ◽  
Author(s):  
HK Holland ◽  
JR Wingard ◽  
WE Beschorner ◽  
R Saral ◽  
GW Santos
Keyword(s):  
Bone Marrow ◽  
Bronchiolitis Obliterans ◽  
Marrow Transplant ◽  
Host Disease ◽  
Allogeneic Bmt ◽  
Serum Igg ◽  
Ventilatory Failure ◽  
Oncology Center ◽  
Low Serum ◽  
Johns Hopkins Oncology

Abstract The records of 549 bone marrow transplant (BMT) patients at The Johns Hopkins Oncology Center during a 9-year period were reviewed to determine the incidence of bronchiolitis obliterans (BrOb). Seven patients had BrOb. All seven died, and BrOb was a contributing cause of death in six patients. Only recipients of allogeneic BMT were at risk for developing BrOb (2% incidence). Three cases were incidentally discovered at autopsy in patients who died less than 120 days after BMT from ventilatory failure owing to interstitial pneumonitis. Four cases were patients who died greater than 120 days after BMT. Of this latter group, all had overt chronic graft-v-host disease (CGVHD). Among 120 day survivors of allogeneic BMT, 6% of those with CGVHD developed BrOb as compared with none of those without CGVHD (P = .008). Five percent of patients with reduced IgG levels at day 120 developed BrOb as compared with none of those with normal IgG (P = .04). The incidence of BrOb in 120-day survivors was 14% (4 of 29) in patients with both CGVHD and decreased serum IgG, whereas patients with CGVHD only (0 of 25), those with decreased IgG levels only (0 of 53), and those with no CGVHD and normal IgG levels (0 of 70) did not develop BrOb.

The Johns Hopkins Oncology Center??s Narcotic Conversion Program

1990 ◽  
Vol 13 (3) ◽  
pp. 203-204
Author(s):  
Jeanne Held
Keyword(s):  
Oncology Center ◽  
Johns Hopkins Oncology

COVID-19 infection and dermatologic surgery: management in a dermo-oncology center in a high-risk pandemic area

2020 ◽  
Vol 155 (5) ◽  
Author(s):  
Simone Ribero ◽  
Virginia Caliendo ◽  
Franco Picciotto ◽  
Maria T. Fierro ◽  
Pietro Quaglino
Keyword(s):  
High Risk ◽  
Dermatologic Surgery ◽  
Oncology Center ◽  
Surgery Management

Evaluation of Rectal Cancer Management in El-Minia Oncology Center

2020 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
mina wahba ◽  
Alaal Khalil ◽  
Mohamed Alkilany ◽  
medhat soliman
Keyword(s):  
Rectal Cancer ◽  
Cancer Management ◽  
Oncology Center
Sign in / Sign up

Export Citation Format

Share Document